[LIVE TRADE DAY] MYOV- Up over 30% after rejecting takeover bid

[Manage your email subscriptions.]( Good morning, Trader! Here are our top 4 trade ideas today. These setups look primed! Be the best prepared trader on the Street!  - [Synaptogenix (SNPX)-]( The Catalyst Trade - TWTR - Twitter closed strong in a weak market Friday on rumors super agent Emanuel pushing for Musk TWTR Settlement - CYTK- JMP securities raises price target from $53 to $82, maintains as Market Outperform - MYOV- Up over 30% after rejecting takeover bid *This is an Issuer-Paid Advertisement, See Disclosure Below  Sponsored By [Synaptogenix (SNPX)-]( The Catalyst Trade A catalyst trade is a classic trading setup, where investors take positions into an upcoming known event (the catalyst), and the increased demand can push the stock price into the news. [SNPX]( has such an upcoming event in that Q4 Phase 2 data for its Alzheimer's drug is set to be released before the end of the year. Q4 begins today, so this potential game changing data could be released any day now! Last week, BIIB announced positive Phase 3 results for its Alzheimer's treatment and its stock went up over 40%, it added over $10 billion in market cap on the news in 1 day. This is the type of game changer a good treatment for Alzheimer’s can be.  According to Finviz, [SNPX]( has a market cap of less than $50 million. That's a far cry from its competitor SAVA which is valued at over $2 billion and the $10 billion BIIB put on in just 1 day. Positive Phase 2 data really would be a game changer for [SNPX](, and I don’t think the market is pricing in this potential just yet. It’s an important quarter for [SNPX]( and the results coming in Q4 2022 could be historic for the company! This is one to keep your eye on! Recently, [SNPX]( President & Chief Scientific Officer Dr. Daniel Alkon appeared on the [TD Ameritrade Network]( to discuss the current business in front of 1000’s of investors. You can watch this short segment [here](. [Boardroom Investing]( has conducted an in depth research report into the company, you can access it [here.](  [ Click Here To Find Out More About the Company Working To Reverse the Effects of Alzheimers, A Multi-Billion Market Opportunity](  *This is an Issuer-Paid Advertisement, See Disclosure Below  Join RagingBull's CEO Jeff Bishop LIVE at[2pm Tomorrow]( in the [Wall Street 360 Chat Room](, and learn how Jeff Williams times the Market to target daily market-neutral trades in real time! Here’s what Jeff William’s students in [Market Navigator]( are saying: with Jeff Williams in [Real-Time](, through [Real Money Trading]( when he’s not in the 360 room [HERE](! [Here is your direct link to the 360 Wall Street Chat Room](  TWTR - Twitter closed strong in a weak market Friday on rumors super agent Emanuel pushing for Musk TWTR Settlement Despite QQQ's closing down 1.7% on Friday, TWTR closed the day up 2.57%, at one point being up 4%. Speculation that super agent Emanuel was in discussions with Musk and TWTR to arrange a settlement sent the stock higher. As a reminder the original offer was to buy TWTR for $54.20 per share in cash with TWTR closing Friday at $43.84.  To the upside there is resistance at $44.50-$45, the next target above that would be $50. To the downside the next target would be Friday’s open of $42.89, then $42 and below that $40.80. There is also a gap to fill at $38.65. [Here is your direct link to the 360 Wall Street Chat Room](  CYTK- JMP securities raises price target from $53 to $82, maintains as Market Outperform CYTK is a biotech company with Phase 3 trials for the treatment of heart failure and spinal muscular atrophy. It's on one of the strongest streaks this year. In a down market it made 52-week highs just a few weeks ago at $55.80.  To the upside the first target would be $50, then $51.50 and then $54 above that in the short-term. To the downside, the first potential support is $48 and $45 below that. [Here is your direct link to the 360 Wall Street Chat Room](   MYOV- Up over 30% after rejecting takeover bid Biotech Myovant rejected a bid by Sumitovant Biopharma, its largest shareholder, to buy the shares it doesn't already own for $22.75. MYOV said the offer significantly undervalues the company.  After closing at $17.96 MYOV traded above $23.50 in the pre-market. To the upside, $24 and $25 are the next potential levels of resistance with $27 above that. To the downside, there is potential support at $22.80, then $20.50. Below that there is a gap to fill at $17.96. [Here is your direct link to the 360 Wall Street Chat Room](  To your success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360.com](  © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, neither Sherwood Ventures, LLC (“Sherwood”) nor Ragingbull.com, LLC (“Raging Bull”) can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Sherwood nor Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. ISSUER-PAID ADVERTISEMENT. Synaptogenix, Inc. (“SNPX” or the “Company”) has paid or will pay Sherwood $30,000 USD per month for three months (the “Initial Term”) in cash, shares of restricted common stock with a value of $150,000, and warrants valued at issuance of $75,000 for marketing services including communicating to the public about the company through Sherwood’s affiliate Raging Bull, among others. This advertisement is part of those issuer-paid marketing services. The contract with SNPX automatically renews for successive one-month periods following the Initial Term (the “Renewal Term”) unless it is terminated by written notice of either party prior to the end of the previous term. During the Renewal Term, SNPX has agreed to pay Sherwood a monthly fee of $30,000 in cash, shares of restricted stock with a value of $50,000 and warrants valued at $25,000. As a result of this advertisement and other marketing efforts, Sherwood and/or Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Sherwood and Raging Bull, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) hold the securities of SNPX and, as permitted by law, may sell those shares during the course of this marketing arrangement or afterwards. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of SNPX, increased trading volume, and possibly an increased share price of the SNPX’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of [RagingBull.com](, LLC are paid in whole or in part by commission based on their sales of Services to subscribers. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.